Neuromedin

Neuromedin U (NMU) regulates osteoblast differentiation and activity.

Osteoporosis is a disease of low bone mass that places individuals at enhanced risk for fracture, disability, and death. Osteoporosis rates are expected to rise significantly in the coming decades yet there are limited pharmacological treatment options, particularly for long-term management of this chronic condition.

The drug development pipeline is relatively bereft of new strategies, causing an urgent and unmet need for developing new strategies and targets for treating osteoporosis. Here, we examine a lesser-studied bone remodeling pathway, Neuromedin U (NMU), which is expressed in the bone microenvironment along with its cognate receptors NMU receptor 1 (NMUR1) and 2 (NMUR2). We independently corroborate a prior report that global loss of NMU expression leads to high bone mass and test the hypothesis that NMU negatively regulates osteoblast differentiation. Consistent with this, in vitro studies reveal NMU represses osteoblastic differentiation of osteogenic precursors but, in contrast, promotes osteoblastic marker expression, proliferation and activity of osteoblast-like cells. Phospho-profiling arrays were used to detail differential signaling outcomes that may underlie the opposite responses of these cell types.

Collectively, our findings indicate that NMU exerts cell-type-specific responses to regulate osteoblast differentiation and activity.


CAPA neuropeptides and their receptor form an anti-diuretic hormone signaling system in the human disease vector, Aedes aegypti.

Insect CAPA neuropeptides are homologs of mammalian neuromedin U and are known to influence ion and water balance by regulating the activity of the Malpighian ‘renal’ tubules (MTs). Several diuretic hormones are known to increase primary fluid and ion secretion by insect MTs and, in adult female mosquitoes, a calcitonin-related peptide (DH31) called mosquito natriuretic peptide, increases sodium secretion to compensate for the excess salt load acquired during blood-feeding. An endogenous mosquito anti-diuretic hormone was recently described, having potent inhibitory activity against select diuretic hormones, including DH31.

Herein, we functionally deorphanized, both in vitro and in vivo, a mosquito anti-diuretic hormone receptor (AedaeADHr) with expression analysis indicating highest enrichment in the MTs where it is localized within principal cells. Characterization using a heterologous in vitro system demonstrated the receptor was highly sensitive to mosquito CAPA neuropeptides while in vivo, AedaeADHr knockdown abolished CAPA-induced anti-diuretic control of DH31-stimulated MTs.

CAPA neuropeptides are produced within a pair of neurosecretory cells in each of the abdominal ganglia, whose axonal projections innervate the abdominal neurohaemal organs, where these neurohormones are released into circulation. Lastly, pharmacological inhibition of nitric oxide synthase (NOS) and protein kinase G (PKG) signaling eliminated anti-diuretic activity of CAPA, highlighting the role of the second messenger cGMP and NOS/PKG in this anti-diuretic signaling pathway.


What is the prognostic value of neuromedin U in patients with hepatocellular carcinoma?

Neuromedin U (NMU) is a neuropeptide belonging to the neuromedin family. Recently, significant associations between NMU and several cancers have been reported. However, no studies have examined the association between NMU and hepatocellular carcinoma (HCC).

The purpose of this study was to examine the role of NMU in HCC.

An enzyme-linked immunosorbent assay was used to measure the level of NMU protein in the sera of patients with hepatic hemangioma and HCC. NMU and cytokine mRNA expression was assessed in HCC samples via RT-qPCR.

Neuromedin N

HY-P0079 10mM/1mL
EUR 253.00

Neuromedin B

HY-P0241 10mg
EUR 725.00

Neuromedin B

H-3280.0001 1.0mg
EUR 126.00
Description: Sum Formula: C52H73N15O12S; CAS# [87096-84-2] net

Neuromedin B

H-3280.0005 5.0mg
EUR 418.00
Description: Sum Formula: C52H73N15O12S; CAS# [87096-84-2] net

Neuromedin B

H-3280.0025 25.0mg
EUR 1578.00
Description: Sum Formula: C52H73N15O12S; CAS# [87096-84-2] net

Neuromedin N

H-4150.0005 5.0mg
EUR 151.00
Description: Sum Formula: C38H63N7O8; CAS# [92169-45-4] net

Neuromedin N

H-4150.0025 25.0mg
EUR 515.00
Description: Sum Formula: C38H63N7O8; CAS# [92169-45-4] net

Neuromedin C (porcine)

B5215-1 1 mg
EUR 213.00

Neuromedin B (porcine)

B5225-1 1 mg
EUR 176.00

Neuromedin B (porcine)

B5225-10 10 mg
EUR 937.00

Neuromedin B (porcine)

B5225-25 25 mg
EUR 1842.00

Neuromedin B (porcine)

B5225-5 5 mg
EUR 556.00

Neuromedin U (rat)

B5231-1 1 mg
EUR 366.00

Neuromedin U (rat)

B5231-5 5 mg
EUR 1286.00

Neuromedin S (rat)

B5466-.5 500 µg
EUR 466.00

Neuromedin U antibody

20R-NR005 50 uL
EUR 532.00
Description: Rabbit polyclonal Neuromedin U antibody

Biotin-Neuromedin B

5-00808 4 x 5mg EUR 0.00

Neuromedin (B-30)

5-01596 4 x 1mg EUR 0.00

Neuromedin (U25), human

5-01597 4 x 1mg EUR 0.00

Neuromedin (U25), porcine

5-01598 4 x 1mg EUR 0.00

Neuromedin (U8), porcine

5-01599 4 x 5mg EUR 0.00

Neuromedin B, porcine

5-01600 4 x 5mg EUR 0.00

Neuromedin S (human)

5-01603 4 x 1mg EUR 0.00

Neuromedin S (rat)

5-01604 4 x 1mg EUR 0.00

Neuromedin U, rat

5-01605 4 x 1mg EUR 0.00

Neuromedin U Antibody

47927-100ul 100ul
EUR 252.00

Neuromedin S antibody

70R-51177 100 ul
EUR 244.00
Description: Purified Polyclonal Neuromedin S antibody

Neuromedin B antibody

70R-51309 100 ul
EUR 244.00
Description: Purified Polyclonal Neuromedin B antibody

Neuromedin B Peptide

20-abx265473
  • EUR 467.00
  • EUR 759.00
  • EUR 342.00
  • 10 mg
  • 25 mg
  • 5 mg
  • Shipped within 5-10 working days.
  • Neuromedin (U8) Peptide

    20-abx265480
    • EUR 411.00
    • EUR 662.00
    • EUR 314.00
    • 10 mg
    • 25 mg
    • 5 mg
  • Shipped within 5-10 working days.
  • Neuromedin N Peptide

    20-abx265805
    • EUR 328.00
    • EUR 495.00
    • EUR 272.00
    • 10 mg
    • 25 mg
    • 5 mg
  • Shipped within 5-10 working days.
  • [Ser2] - Neuromedin C

    5-00300 4 x 5mg EUR 0.00

    Neuromedin U, rat

    HY-P1238 5mg
    EUR 991.00

    Neuromedin S (rat)

    H-6228.0500 0.5mg
    EUR 454.00
    Description: Sum Formula: C193H307N57O49S; CAS# [843782-19-4] net

    Neuromedin S (rat)

    H-6228.1000 1.0mg
    EUR 696.00
    Description: Sum Formula: C193H307N57O49S; CAS# [843782-19-4] net

    Neuromedin S (human)

    H-6232.0500 0.5mg
    EUR 454.00
    Description: Sum Formula: C173H265N53O44; CAS# [1138204-27-9] net

    Neuromedin S (human)

    H-6232.1000 1.0mg
    EUR 696.00
    Description: Sum Formula: C173H265N53O44; CAS# [1138204-27-9] net

    Neuromedin U Blocking Peptide

    20-abx161970
    • EUR 272.00
    • EUR 411.00
    • 1 mg
    • 5 mg
  • Shipped within 5-10 working days.
  • neuromedin U Peptide (OVA)

    20-abx165578
    • EUR 578.00
    • EUR 258.00
    • EUR 1720.00
    • EUR 690.00
    • EUR 425.00
    • 100 ug
    • 10 ug
    • 1 mg
    • 200 ug
    • 50 ug
  • Shipped within 5-7 working days.
  • Neuromedin B (NMB) Antibody

    20-abx100840
    • EUR 411.00
    • EUR 133.00
    • EUR 1135.00
    • EUR 551.00
    • EUR 314.00
    • 100 ug
    • 10 ug
    • 1 mg
    • 200 ug
    • 50 ug
  • Shipped within 5-7 working days.
  • Neuromedin S Blocking Peptide

    20-abx064052
    • EUR 272.00
    • EUR 411.00
    • 1 mg
    • 5 mg
  • Shipped within 5-10 working days.
  • Neuromedin B Blocking Peptide

    20-abx064184
    • EUR 272.00
    • EUR 411.00
    • 1 mg
    • 5 mg
  • Shipped within 5-10 working days.
  • Neuromedin U (NMU) Antibody

    20-abx133261
    • EUR 300.00
    • EUR 439.00
    • EUR 189.00
    • 100 ul
    • 200 ul
    • 30 ul
  • Shipped within 5-10 working days.
  • Neuromedin B (NMB) Antibody

    20-abx128133
    • EUR 398.00
    • EUR 133.00
    • EUR 1107.00
    • EUR 537.00
    • EUR 314.00
    • 100 ug
    • 10 ug
    • 1 mg
    • 200 ug
    • 50 ug
  • Shipped within 5-7 working days.